

HORIZONSAMI

**A Prospective, Randomized Comparison of
Paclitaxel-eluting TAXUS Stents vs. Bare
Metal Stents During Primary Angioplasty in
Acute Myocardial Infarction**

– One Year Results –


Gregg W. Stone MD

For the HORIZONS-AMI Investigators

HORIZONSAMI


Harmonizing Outcomes with Revascularization and Stents in AMI

3602 pts with STEMI with symptom onset ≤ 12 hours




HORIZONSAMI

Harmonizing Outcomes with Revascularization and Stents in AMI




Primary Efficacy Endpoint: Ischemic TLR



Number at risk

TAXUS DES	2257	2132	2098	2069	1868
EXPRESS BMS	749	697	675	658	603


Secondary Efficacy Endpoint: **Ischemic TVR**



Number at risk

TAXUS DES	2257	2119	2078	2045	1848
EXPRESS BMS	749	695	669	650	598

Primary Safety Endpoint: **Safety MACE***




Number at risk

TAXUS DES	2257	2115	2086	2057	1856
EXPRESS BMS	749	697	683	672	619

* Safety MACE = death, reinfarction, stroke, or stent thrombosis


One-Year All-Cause Mortality



Number at risk

TAXUS DES	2257	2180	2161	2147	1949
EXPRESS BMS	749	716	712	702	648


One-Year Death or Reinfarction



Number at risk

TAXUS DES	2257	2140	2110	2083	1882
EXPRESS BMS	749	703	689	678	625


Stent Thrombosis (ARC Definite or Probable)



Number at risk


TAXUS DES	2238	2122	2098	2078	1884
EXPRESS BMS	744	701	694	683	629

Angiographic Follow-up




* Randomized in stent arm; stent procedure successful (DS <10%, TIMI-3 flow, ≤NHLBI type A peri-stent dissection); no stent thrombosis or CABG w/i 30 days

Angiographic Late Loss at 13 Month Lesions with Stents Implanted



Binary Angiographic Restenosis at 13 Months Lesions with Stents Implanted

■ TAXUS DES (n=1066) ■ EXPRESS BMS (n=328)



Conclusions

- ▬ In this large-scale, prospective, randomized trial of pts with STEMI undergoing primary stenting, the implantation of paclitaxel-eluting TAXUS stents compared to bare metal EXPRESS stents resulted in:
 - A significant 41% reduction in the 1-year primary efficacy endpoint of ischemia-driven TLR, and a significant 56% reduction in the 13 month major secondary efficacy endpoint of binary restenosis
 - Non inferior rates of the primary composite safety endpoint of all cause death, reinfarction, stent thrombosis or stroke at 1-year

Conclusions

- The long-term safety and efficacy profile of paclitaxel-eluting TAXUS stents compared to bare metal EXPRESS stents in STEMI will be determined by the ongoing 5 year follow-up of patients randomized in the HORIZONS-AMI trial